石药集团(01093.HK) 公布,集团开发的SYS6040(抗体偶联药物)的新药临床试验申请已获得美国食品药品监督管理局批准,可以在美国开展临床研究。该产品亦于2025年3月获得国家药监局批准在中国开展临床试验。集团指,该产品为一款单克隆抗体偶联药物,与肿瘤表面的特异性受体结合,通过内吞作用进入细胞并释放毒素,达到杀伤肿瘤细胞的作用。本次获批的临床适应症为晚期实体瘤。临床前研究显示,该产品对多种...
Source Link石药集团(01093.HK) 公布,集团开发的SYS6040(抗体偶联药物)的新药临床试验申请已获得美国食品药品监督管理局批准,可以在美国开展临床研究。该产品亦于2025年3月获得国家药监局批准在中国开展临床试验。集团指,该产品为一款单克隆抗体偶联药物,与肿瘤表面的特异性受体结合,通过内吞作用进入细胞并释放毒素,达到杀伤肿瘤细胞的作用。本次获批的临床适应症为晚期实体瘤。临床前研究显示,该产品对多种...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.